DHF
MCID: DNG002
MIFTS: 60

Dengue Hemorrhagic Fever (DHF)

Categories: Blood diseases, Infectious diseases

Aliases & Classifications for Dengue Hemorrhagic Fever

MalaCards integrated aliases for Dengue Hemorrhagic Fever:

Name: Dengue Hemorrhagic Fever 12 54 15 17
Dengue Haemorrhagic Fever 12 32
Severe Dengue 43 71
Dhf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12206
MeSH 43 D019595
NCIt 49 C34683
SNOMED-CT 67 20927009
ICD10 32 A91
UMLS 71 C0019100

Summaries for Dengue Hemorrhagic Fever

Disease Ontology : 12 A dengue disease that occurs when a person experiences a second infection with a heterologous Dengue virus serotype, which is transmitted by Aedes mosquito bite. The infection has symptom hemorrhagic lesions of the skin, has symptom thrombocytopenia, has symptom reduction in the fluid part of the blood, and has symptom high fever.

MalaCards based summary : Dengue Hemorrhagic Fever, also known as dengue haemorrhagic fever, is related to dengue disease and cholecystitis, and has symptoms including thrombocytopenia, high fever and hemorrhagic lesions of the skin. An important gene associated with Dengue Hemorrhagic Fever is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include endothelial, t cells and liver, and related phenotypes are hematopoietic system and immune system

Related Diseases for Dengue Hemorrhagic Fever

Diseases related to Dengue Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 857)
# Related Disease Score Top Affiliating Genes
1 dengue disease 33.8 TNF IFNB1 IFNA1 CD40LG CD209
2 cholecystitis 31.5 GPT F2 ALB
3 acute liver failure 31.4 GPT F2 ALB
4 dengue shock syndrome 31.4 TNF IL6 IFNA1 HLA-A CD40LG CD209
5 pancreatitis 31.3 TNF IL6 IL10 ALB
6 acute kidney failure 31.3 GPT F2 ALB
7 pulmonary edema 31.3 TNF IL10 F2 CXCL8
8 disseminated intravascular coagulation 31.0 TNF IL6 IL10 GPT F3 F2
9 chikungunya 31.0 TNF STAT1 IL6 CD209
10 japanese encephalitis 31.0 TNF TLR3 IFNB1 IFNA1 CD209
11 hemophagocytic lymphohistiocytosis 30.9 TNF IL10 IFNG GPT CXCL8
12 hepatic coma 30.9 GPT F3 F2 ALB
13 acute pancreatitis 30.9 TNF IL6 IL10 GPT CXCL8 ALB
14 active peptic ulcer disease 30.8 F3 F2 ALB
15 cardiac tamponade 30.8 F3 F2 ALB
16 metabolic acidosis 30.8 IL6 GPT F2 ALB
17 femoral neuropathy 30.8 F3 F2
18 hepatic encephalopathy 30.7 TNF IL6 GPT F2 ALB
19 eclampsia 30.7 TNF IL6 F2 ALB
20 filariasis 30.7 TNF IL6 IL10 IFNG ALB
21 compartment syndrome 30.7 TNF IL6 GPT F3 F2 ALB
22 crohn's colitis 30.7 TNF IFNG CXCL8
23 analbuminemia 30.7 GPT F3 F2 ALB
24 gastritis 30.7 TNF IL6 IL10 CXCL8
25 acalculous cholecystitis 30.7 GPT F2 CD40LG ALB
26 lymphopenia 30.6 IL6 IL4 IL10 IFNG
27 peptic ulcer disease 30.6 TNF IL10 CXCL8 ALB
28 hemorrhagic disease 30.6 F3 F2 CD40LG
29 acute myocarditis 30.6 TNF TLR3 STAT1 IL10
30 haemophilus influenzae 30.6 TNF CXCL8
31 endophthalmitis 30.6 TNF IL6 CXCL8 ALB
32 hepatitis 30.6 TNF IFNG IFNA1 GPT F2
33 allergic hypersensitivity disease 30.6 TNF IL4 IL10 IFNG CXCL8
34 myositis 30.5 TNF IL6 IFNG IFNA1 CXCL8
35 coccidioidomycosis 30.5 TNF STAT1 CD40LG
36 acute disseminated encephalomyelitis 30.5 IL10 IFNB1 CD40LG
37 yellow fever 30.5 STAT1 IL6 IL4 IFNB1 IFNAR1
38 cholestasis 30.5 TNF IL6 GPT F2 ALB
39 adult respiratory distress syndrome 30.4 TNF IL6 IL10 F2 CXCL8
40 bacterial sepsis 30.4 TNF TLR3 IL6 IL10 CXCL8
41 guillain-barre syndrome 30.4 TNF CD40LG ALB
42 stroke, ischemic 30.4 TNF IL6 F3 F2 ALB
43 anuria 30.3 GPT F3 F2 CD40LG ALB
44 epidemic typhus 30.3 IL10 GPT CD40LG
45 chronic kidney disease 30.3 TNF IL6 IL10 HLA-A ALB
46 necrotizing fasciitis 30.3 IL6 CXCL8 ALB
47 vasculitis 30.3 TNF IL6 IL10 CD40LG
48 appendicitis 30.3 TNF IL6 IL10 IFNG CXCL8 ALB
49 gastric ulcer 30.2 TNF IL6 CXCL8
50 polyneuropathy 30.2 TNF IL6 CD40LG ALB

Graphical network of the top 20 diseases related to Dengue Hemorrhagic Fever:



Diseases related to Dengue Hemorrhagic Fever

Symptoms & Phenotypes for Dengue Hemorrhagic Fever

Symptoms:

12
  • thrombocytopenia
  • high fever
  • hemorrhagic lesions of the skin
  • reduction in the fluid part of the blood

MGI Mouse Phenotypes related to Dengue Hemorrhagic Fever:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 CD40LG F2 F3 FCGR2A HLA-A IFNAR1
2 immune system MP:0005387 10.38 ALB CD40LG F2 F3 FCGR2A HLA-A
3 homeostasis/metabolism MP:0005376 10.31 ALB CD40LG F2 F3 IFNAR1 IFNB1
4 cardiovascular system MP:0005385 10.29 ALB CD40LG F2 F3 IFNAR1 IFNG
5 mortality/aging MP:0010768 10.28 ALB CD40LG F2 F3 FCGR2A HLA-A
6 endocrine/exocrine gland MP:0005379 10.26 ALB CD40LG HLA-A IFNAR1 IFNG IL10
7 digestive/alimentary MP:0005381 10.19 ALB F2 IFNAR1 IFNG IL10 IL4
8 integument MP:0010771 10.16 CD40LG F2 F3 IFNAR1 IFNG IL10
9 liver/biliary system MP:0005370 10.03 ALB IFNAR1 IFNG IL10 IL4 IL6
10 nervous system MP:0003631 10.03 CD40LG F2 F3 HLA-A IFNB1 IFNG
11 neoplasm MP:0002006 10.02 ALB F3 IFNAR1 IFNB1 IFNG IL10
12 muscle MP:0005369 9.97 ALB F3 IFNG IL10 IL6 STAT1
13 no phenotypic analysis MP:0003012 9.7 HLA-A IFNAR1 IFNB1 IFNG IL10 IL4
14 respiratory system MP:0005388 9.61 F2 F3 IFNG IL10 IL4 IL6
15 skeleton MP:0005390 9.4 CD40LG F2 FCGR2A GPT IFNAR1 IFNB1

Drugs & Therapeutics for Dengue Hemorrhagic Fever

Drugs for Dengue Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
3 Anti-Allergic Agents Phase 4
4 Histamine Antagonists Phase 4
5 Histamine H1 Antagonists Phase 4
6
Histamine Phosphate Phase 4 51-74-1 65513
7 Dermatologic Agents Phase 4
8 Neurotransmitter Agents Phase 4
9
tannic acid Approved Phase 3 1401-55-4
10
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
11 Immunologic Factors Phase 3
12 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
13 Pharmaceutical Solutions Phase 3
14
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
15
Ivermectin Approved, Investigational, Vet_approved Phase 2 70288-86-7 6474909
16 Hemostatics Phase 2
17 Vaccines Phase 2
18 Immunoglobulins Phase 1, Phase 2
19 Antibodies Phase 1, Phase 2
20 Antiparasitic Agents Phase 2
21 Anti-Infective Agents Phase 2
22
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
23
Aluminum sulfate Approved Phase 1 10043-01-3
24 Antacids Phase 1
25 Anti-Ulcer Agents Phase 1
26 Adjuvants, Immunologic Phase 1
27 Gastrointestinal Agents Phase 1
28 Mitogens
29 Endothelial Growth Factors
30 Rho(D) Immune Globulin
31 Immunoglobulins, Intravenous
32 gamma-Globulins

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 The Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as a Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
3 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
4 Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
5 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT01374516 Phase 3
6 Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico Completed NCT01411241 Phase 3
7 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines Completed NCT02992418 Phase 3
8 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
9 Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru Completed NCT01436396 Phase 3
10 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia Completed NCT02993757 Phase 3
11 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico Completed NCT02979535 Phase 3
12 Albumin 5% as Resuscitation in Adult Dengue Fever Patients With Plasma Leakage Recruiting NCT04076254 Phase 3 Albumins;Fluid
13 A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Comparison of Recombinant Factor VIIa (NovoSeven®) and Standard Haemostatic Replacement Therapy in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2 activated recombinant human factor VII;placebo
14 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam Completed NCT00875524 Phase 2
15 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT00993447 Phase 2
16 Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine Completed NCT00730288 Phase 2
17 Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years Completed NCT00740155 Phase 2
18 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru Completed NCT00788151 Phase 2
19 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in South America Completed NCT01187433 Phase 2
20 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
21 Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
22 Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore Completed NCT00880893 Phase 2
23 Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India. Completed NCT01550289 Phase 2
24 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore Completed NCT02824198 Phase 2
25 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America Completed NCT02623725 Phase 2
26 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults. Completed NCT01488890 Phase 2
27 Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand Completed NCT00842530 Phase 2
28 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
29 Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
30 Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children Completed NCT00468858 Phase 2
31 Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Recruiting NCT03432442 Phase 2 Ivermectin
32 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil Active, not recruiting NCT02741128 Phase 2
33 Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1 , 2 , or 3 Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines Active, not recruiting NCT02628444 Phase 2
34 Phase 1 Study of the Safety and Immunogenicity of rDEN2/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 2 Completed NCT00094705 Phase 1
35 Phase I Study of the Safety and Immunogenicity of rDEN1delta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 1 Completed NCT00089908 Phase 1
36 A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3delta30/31‐7164, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3 Completed NCT00831012 Phase 1
37 Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-200,201, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4 Completed NCT00270699 Phase 1
38 Evaluation of the Safety and Immunogenicity of Heterologous Dengue Vaccine Administration in Dengue Immune Individuals Completed NCT00458120 Phase 1
39 A Phase 1 Study To Evaluate The Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue (Serotype 1, 2, 3, and 4) Plasmid DNA Vaccine (TVDV) Formulated With and Without Vaxfectin® Completed NCT01502358 Phase 1
40 A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3-3'Ddelta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3 Completed NCT00712803 Phase 1
41 Phase I Evaluation of the Safety and Immunogenicity of rDEN4delta30 Lot# 109A, a Live Attenuated DEN4 Vaccine, in Healthy Flavivirus-naïve Adult Volunteers. Completed NCT00919178 Phase 1
42 Phase 1, Placebo-Controlled, Double-Blind, Safety Study of HBV-001 D1 in Healthy Adults Completed NCT00936429 Phase 1
43 Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-4995, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4 Completed NCT00322946 Phase 1
44 A Phase I Evaluation of the Safety and Immunogenicity of the rDEN1∆30 Dengue Serotype 1 Vaccine Given at a Single Dose of 101 PFU in Healthy Flavivirus-naïve Adult Subjects Completed NCT01084291 Phase 1
45 A Phase I Evaluation of the Safety and Immunogenicity of rDEN2/4 Δ30(ME) Dengue Serotype 2 Vaccine Given at 10^1 PFU in Healthy Flavivirus-naïve Adult Subjects Completed NCT01073306 Phase 1
46 Safety and Immunogenicity of a 2-Dose Regimen of rDEN1delta30 Dengue Serotype 1 Vaccine With Boosting at 4 Versus 6 Months Completed NCT00473135 Phase 1
47 A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of Walter Reed Army Institute of Research (WRAIR) Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) in Healthy Adults in a Non-Endemic Region Completed NCT01666652 Phase 1
48 A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of WRAIR Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) in Healthy Adults in Puerto Rico Completed NCT01702857 Phase 1
49 A Phase 1 Evaluation of the Safety and Immunogenicity of Five Admixtures of TetraVax-DV, a Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine, in Healthy Flavivirus-naïve Adult Subjects Completed NCT01072786 Phase 1
50 A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-Naïve Adult Subjects Completed NCT01436422 Phase 1

Search NIH Clinical Center for Dengue Hemorrhagic Fever

Cochrane evidence based reviews: severe dengue

Genetic Tests for Dengue Hemorrhagic Fever

Anatomical Context for Dengue Hemorrhagic Fever

MalaCards organs/tissues related to Dengue Hemorrhagic Fever:

40
Endothelial, T Cells, Liver, Skin, Monocytes, Testes, Kidney

Publications for Dengue Hemorrhagic Fever

Articles related to Dengue Hemorrhagic Fever:

(show top 50) (show all 2713)
# Title Authors PMID Year
1
Super induction of dengue virus NS1 protein in E. coli. 54 61
19232392 2009
2
TNF and LTA gene, allele, and extended HLA haplotype associations with severe dengue virus infection in ethnic Thais. 61 54
19392621 2009
3
Recombinant non-structural 1 (NS1) protein of dengue-2 virus interacts with human STAT3beta protein. 61 54
15878791 2005
4
High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. 61 54
12355369 2002
5
Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. 54 61
11724841 2001
6
Early dengue outbreak detection modeling based on dengue incidences in Singapore during 2012 to 2017. 61
32232863 2020
7
The association of obesity and severe dengue: possible pathophysiological mechanisms. 61
32413364 2020
8
Comprehensive treatment in severe dengue during preterm and term labor: could tocolysis be useful? 61
30626246 2020
9
The spectrum of disease severity, the burden of hospitalizations and associated risk factors in confirmed dengue among persons of all ages: findings from a population based longitudinal study from Barbados. 61
32286109 2020
10
The importance of effective risk communication and transparency: lessons from the dengue vaccine controversy in the Philippines. 61
32518285 2020
11
Triple positivity for nonstructural antigen 1, immunoglobulin M and immunoglobulin G is predictive of severe thrombocytopaenia related to dengue infection. 61
32554305 2020
12
Towards Predicting Progression to Severe Dengue. 61
31982232 2020
13
Posterior Reversible Encephalopathy (PRES) in a Child with Severe Dengue. 61
31501883 2020
14
Multivariate time-series analysis of biomarkers from a dengue cohort offers new approaches for diagnosis and prognosis. 61
32544159 2020
15
Risk factors and fogging effectiveness of dengue hemorrhagic fever incidence in the Pontap Public Health Center area in Palopo City, Indonesia. 61
32545071 2020
16
TLR2 on blood monocytes senses dengue virus infection and its expression correlates with disease pathogenesis. 61
32576819 2020
17
Clinical, Virological, and Cytokine Profiles of Children Infected with Dengue Virus during the Outbreak in Southern Vietnam in 2017. 61
32189614 2020
18
Effectiveness of mosquito nests eradication abatezation for elimination of Aedes aegypti. 61
32545117 2020
19
Retrospective cross-sectional observational study on the epidemiological profile of dengue cases in Pernambuco state, Brazil, between 2015 and 2017. 61
32532240 2020
20
Imported dengue serotype 1 outbreak in a non-endemic region, China, 2017: A molecular and seroepidemiological study. 61
32535157 2020
21
Renal Manifestations in Children with Dengue Fever Hospitalized in Pediatric Intensive Care Unit. 61
32557142 2020
22
Roles of Macrophage Migration Inhibitory Factor in Dengue Pathogenesis: From Pathogenic Factor to Therapeutic Target. 61
32545679 2020
23
The atypical lymphocyte count: a novel predictive factor for severe thrombocytopenia related to dengue. 61
31925430 2020
24
Land Use Changes and Cluster Identification of Dengue Hemorrhagic Fever Cases in Bandung, Indonesia. 61
32370258 2020
25
Hopf bifurcation and global dynamics of time delayed Dengue model. 61
32531718 2020
26
Primary Dengue Infection in Patients Requiring Hospitalization During an Outbreak in a Low Incidence Mexican Region. 61
31934823 2020
27
T-cells producing multiple combinations of IFNγ, TNF and IL10 are associated with mild forms of dengue infection. 61
32128816 2020
28
Establishment of Murine Infection Models with Biological Clones of Dengue Viruses Derived from a Single Clinical Viral Isolate. 61
32451883 2020
29
A new player in the game: platelet-derived extracellular vesicles in dengue hemorrhagic fever. 61
32310724 2020
30
Dengue virus non-structural protein 1 activates the p38 MAPK pathway to decrease barrier integrity in primary human endothelial cells. 61
32141809 2020
31
Antibody-Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections. 61
32236481 2020
32
Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. 61
32197107 2020
33
Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. 61
32197105 2020
34
Maternal and Neonatal Outcomes during Dengue Infection Outbreak at a Tertiary National Hospital in Endemic Area of Indonesia. 61
32311872 2020
35
Cytokine Expression in Dengue Fever and Dengue Hemorrhagic Fever Patients with Bleeding and Severe Hepatitis. 61
32124729 2020
36
Dengue Fever and Severe Dengue in Barbados, 2008-2016. 61
32370128 2020
37
Levels of 25-hydroxy Vitamin D3 and Vitamin D Receptor Polymorphism in Severe Dengue Cases from New Delhi. 61
32375246 2020
38
Production and immunogenicity of Fubc subunit protein redesigned from DENV envelope protein. 61
32232529 2020
39
Infection severity across scales in multi-strain immuno-epidemiological Dengue model structured by host antibody level. 61
32157381 2020
40
Pro-Inflammatory Cytokines Are Modulated in Vietnamese Patients with Dengue Fever. 61
32456596 2020
41
A Review on the Progress and Prospects of Dengue Drug Discovery Targeting NS5 RNA- Dependent RNA Polymerase. 61
32445444 2020
42
Molecular characteristics of dengue viruses in patients hospitalized at the Bamrasnaradura Infectious Diseases Institute, Thailand. 61
32475871 2020
43
Dengue Infection Complicated by Hemophagocytic Lymphohistiocytosis: Experiences From 180 Patients With Severe Dengue. 61
31188423 2020
44
Expression Pattern of Selected Toll-like Receptors (TLR's) in the PBMC's of Severe and Non-severe Dengue Cases. 61
31475595 2020
45
Cutaneous Dengue Virus Inoculation Triggers Strong B Cell Reactions but Contrastingly Poor T Cell Responses. 61
32314276 2020
46
Suppressed humoral immunity is associated with dengue nonstructural protein NS1-elicited anti-death receptor antibody fractions in mice. 61
32286343 2020
47
Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement. 61
32305868 2020
48
Severe Dengue Epidemic, Sri Lanka, 2017. 61
32186490 2020
49
An outbreak of dengue fever in children in the National Capital District of Papua New Guinea in 2016. 61
32330106 2020
50
Interferon lambda 1 is associated with dengue severity in Thailand. 61
31981768 2020

Variations for Dengue Hemorrhagic Fever

Expression for Dengue Hemorrhagic Fever

LifeMap Discovery
Genes differentially expressed in tissues of Dengue Hemorrhagic Fever patients vs. healthy controls: 35 (show top 50) (show all 120)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CD38 CD38 molecule Blood + 4.80 0.000
2 IFI27 interferon, alpha-inducible protein 27 Blood + 4.71 0.000
3 RRM2 ribonucleotide reductase M2 Blood + 4.63 0.000
4 IGHM immunoglobulin heavy constant mu Blood + 4.61 0.000
5 BIRC5 baculoviral IAP repeat containing 5 Blood + 4.47 0.000
6 CAV1 caveolin 1, caveolae protein, 22kDa Blood + 4.41 0.000
7 DLGAP5 discs, large (Drosophila) homolog-associated protein 5 Blood + 4.31 0.000
8 XIST X inactive specific transcript (non-protein coding) Blood - 4.31 0.023
9 CEP55 centrosomal protein 55kDa Blood + 4.28 0.000
10 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Blood + 4.21 0.000
11 SHCBP1 SHC SH2-domain binding protein 1 Blood + 4.13 0.000
12 PBK PDZ binding kinase Blood + 4.13 0.000
13 IGKV3-20 immunoglobulin kappa variable 3-20 Blood + 4.13 0.000
14 TYMS thymidylate synthetase Blood + 4.07 0.000
15 CDCA2 cell division cycle associated 2 Blood + 4.06 0.000
16 MKI67 marker of proliferation Ki-67 Blood + 4.00 0.000
17 CYAT1 immunoglobulin lambda light chain-like Blood + 3.98 0.000
18 MCM10 minichromosome maintenance 10 replication initiation factor Blood + 3.98 0.000
19 NOV nephroblastoma overexpressed Blood - 3.97 0.000
20 ZWINT ZW10 interacting kinetochore protein Blood + 3.96 0.000
21 CDK1 cyclin-dependent kinase 1 Blood + 3.92 0.000
22 HMMR hyaluronan-mediated motility receptor (RHAMM) Blood + 3.90 0.000
23 SDC1 syndecan 1 Blood + 3.89 0.000
24 SPC25 SPC25, NDC80 kinetochore complex component Blood + 3.84 0.000
25 NCAPG non-SMC condensin I complex, subunit G Blood + 3.84 0.000
26 TK1 thymidine kinase 1, soluble Blood + 3.82 0.000
27 CDC20 cell division cycle 20 Blood + 3.80 0.000
28 TNFRSF17 tumor necrosis factor receptor superfamily, member 17 Blood + 3.80 0.000
29 DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) Blood + 3.80 0.000
30 TOP2A topoisomerase (DNA) II alpha Blood + 3.80 0.000
31 PI3 peptidase inhibitor 3, skin-derived Blood - 3.76 0.000
32 GLDC glycine dehydrogenase (decarboxylating) Blood + 3.75 0.000
33 IGLJ3 immunoglobulin lambda joining 3 Blood + 3.75 0.000
34 SESN3 sestrin 3 Blood - 3.75 0.000
35 KIF2C kinesin family member 2C Blood + 3.74 0.000
36 CDT1 chromatin licensing and DNA replication factor 1 Blood + 3.72 0.000
37 CDKN3 cyclin-dependent kinase inhibitor 3 Blood + 3.71 0.000
38 KIAA0101 KIAA0101 Blood + 3.71 0.000
39 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood + 3.71 0.034
40 CNTNAP3 contactin associated protein-like 3 Blood - 3.70 0.000
41 CENPA centromere protein A Blood + 3.69 0.000
42 TTK TTK protein kinase Blood + 3.67 0.000
43 ASPM abnormal spindle microtubule assembly Blood + 3.66 0.000
44 KIF11 kinesin family member 11 Blood + 3.64 0.000
45 IGL immunoglobulin lambda locus Blood + 3.64 0.000
46 CCNB2 cyclin B2 Blood + 3.61 0.000
47 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Blood + 3.60 0.000
48 CDC6 cell division cycle 6 Blood + 3.60 0.000
49 SLC2A5 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 Blood + 3.60 0.000
50 DUSP5 dual specificity phosphatase 5 Blood + 3.60 0.000
Search GEO for disease gene expression data for Dengue Hemorrhagic Fever.

Pathways for Dengue Hemorrhagic Fever

Pathways related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TNF TLR3 STAT2 STAT1 IL6 IL4
2
Show member pathways
13.78 TNF IL6 IL4 IL10 IFNG IFNB1
3
Show member pathways
13.66 TNF STAT2 STAT1 IL6 IL4 IL10
4
Show member pathways
13.52 TNF TLR3 STAT2 STAT1 IL6 IL4
5
Show member pathways
13.33 TNF STAT2 STAT1 IL6 IL4 IL10
6
Show member pathways
13.16 TNF TLR3 STAT2 STAT1 IL6 IL10
7
Show member pathways
13.13 TNF TLR3 STAT2 STAT1 IL6 IL4
8
Show member pathways
13.07 TNF TLR3 STAT2 STAT1 IL6 IFNB1
9 12.99 STAT2 STAT1 IL6 IL4 IFNG IFNAR1
10
Show member pathways
12.94 TNF STAT1 IL6 IL4 IL10 IFNG
11
Show member pathways
12.87 TNF TLR3 STAT1 IL6 IFNB1 IFNA1
12 12.85 TNF TLR3 STAT2 STAT1 IL6 IFNG
13
Show member pathways
12.76 TNF IL4 IL10 IFNG IFNAR1 CD40LG
14
Show member pathways
12.75 TNF STAT1 IL6 IL4 IL10 IFNG
15
Show member pathways
12.72 TNF STAT1 IL6 IL4 IL10 IFNG
16
Show member pathways
12.72 TNF STAT1 IL6 IL10 IFNG F2
17
Show member pathways
12.69 STAT2 STAT1 IFNG IFNB1 IFNAR1 IFNA1
18
Show member pathways
12.67 TNF IL4 IFNG IFNB1 IFNAR1 IFNA1
19
Show member pathways
12.64 TNF IFNG IFNB1 IFNA1 CXCL8
20 12.64 TNF TLR3 STAT2 STAT1 IL4 IL10
21
Show member pathways
12.58 STAT2 STAT1 IL6 IL4 IL10 IFNG
22
Show member pathways
12.49 TNF IL6 IL4 IFNG F2 ALB
23
Show member pathways
12.47 TNF TLR3 STAT1 IL6 IFNG CXCL8
24
Show member pathways
12.46 TNF IL6 IL4 IFNG CXCL8
25
Show member pathways
12.44 TNF TLR3 STAT2 STAT1 IL6 IFNG
26
Show member pathways
12.43 TNF STAT1 IL4 IL10 IFNG FCGR2A
27
Show member pathways
12.4 TNF IL6 IL10 CXCL8
28 12.39 TNF IL6 FCGR2A F2 CXCL8
29
Show member pathways
12.39 TNF TLR3 IL6 IFNB1 CXCL8
30
Show member pathways
12.37 TNF STAT2 STAT1 IL6 IL10 CD209
31
Show member pathways
12.36 TNF STAT1 IL6 IL4 IFNG IFNB1
32 12.32 TNF TLR3 STAT1 IL6 IFNG
33 12.29 TNF STAT2 STAT1 IL6 IFNB1 IFNAR1
34 12.26 TNF IL6 IL10 CXCL8
35 12.22 TNF STAT2 STAT1 IFNG IFNB1 IFNAR1
36 12.18 TNF IL6 IL4 IFNG FCGR2A CXCL8
37
Show member pathways
12.17 STAT2 STAT1 IL4
38 12.17 TNF IL6 IL10 IFNB1 CXCL8
39 12.17 TNF IL6 IL4 IL10 IFNG FCGR2A
40 12.16 TNF STAT2 STAT1 IL6
41 12.16 TNF STAT1 IL6 IL4 IL10 CXCL8
42
Show member pathways
12.15 TNF TLR3 STAT2 STAT1 IFNG IFNB1
43
Show member pathways
12.09 STAT1 IL4 IFNG HLA-A
44 12.09 TNF IL6 IL10 IFNG CXCL8
45 12.08 TNF STAT1 IL6 F3 CXCL8
46
Show member pathways
12.08 TNF TLR3 STAT2 STAT1 IL6 IL10
47 12.06 IL6 IFNG IFNB1 CXCL8
48 12.06 TNF STAT1 IL6 IL10 IFNG IFNB1
49
Show member pathways
12.03 TLR3 STAT1 IL6 IL4 IFNG
50 12 TNF IL6 IFNG CXCL8

GO Terms for Dengue Hemorrhagic Fever

Cellular components related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TNF IL6 IL4 IL10 IFNG IFNB1
2 cell surface GO:0009986 9.63 TNF TLR3 HLA-A F3 CD40LG CD209
3 extracellular space GO:0005615 9.47 TNF TLR3 IL6 IL4 IL10 IFNG

Biological processes related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.32 TLR3 STAT2 STAT1 IL6 IL4 IL10
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 TNF TLR3 STAT2 STAT1 IL6 IL4
3 adaptive immune response GO:0002250 10.1 IFNG IFNB1 IFNA1 HLA-A CD209
4 inflammatory response GO:0006954 10.09 TNF TLR3 IL6 CXCL8 CD40LG
5 positive regulation of gene expression GO:0010628 10.09 TNF TLR3 IL6 IL4 IFNG F3
6 regulation of immune response GO:0050776 10.01 IL4 HLA-A FCGR2A CD40LG
7 immune response GO:0006955 10.01 TNF IL6 IL4 IL10 IFNG HLA-A
8 blood coagulation GO:0007596 9.99 IFNB1 IFNA1 F3 F2
9 cellular response to lipopolysaccharide GO:0071222 9.98 TNF IL6 IL10 CXCL8
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.95 TNF TLR3 IL6 CD40LG
11 response to virus GO:0009615 9.92 TNF TLR3 IFNG IFNB1 IFNAR1
12 interferon-gamma-mediated signaling pathway GO:0060333 9.88 STAT1 IFNG HLA-A
13 response to glucocorticoid GO:0051384 9.88 TNF IL6 IL10
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 TNF STAT1 IL6
15 positive regulation of interleukin-6 production GO:0032755 9.86 TNF TLR3 IL6
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 TNF IL6 IL4 IFNG
17 positive regulation of T cell proliferation GO:0042102 9.85 IL6 IL4 CD40LG CD209
18 B cell differentiation GO:0030183 9.83 IL4 IL10 IFNB1 IFNA1 CD40LG
19 extrinsic apoptotic signaling pathway GO:0097191 9.82 TNF TLR3 IFNG
20 B cell proliferation GO:0042100 9.81 IL10 IFNB1 IFNA1 CD40LG
21 response to exogenous dsRNA GO:0043330 9.8 TLR3 IFNB1 IFNA1
22 positive regulation of cytokine secretion GO:0050715 9.8 TNF IL10 IFNG
23 positive regulation of JAK-STAT cascade GO:0046427 9.8 TNF IL6 IL10 F2
24 defense response to virus GO:0051607 9.8 TLR3 STAT2 STAT1 IL6 IFNG IFNB1
25 JAK-STAT cascade GO:0007259 9.78 STAT2 STAT1 IFNG IFNAR1
26 positive regulation of interleukin-12 production GO:0032735 9.77 TLR3 IFNG CD40LG
27 humoral immune response GO:0006959 9.77 TNF IL6 IFNG IFNB1 IFNA1
28 cellular response to interferon-beta GO:0035458 9.76 TLR3 STAT1 IFNB1
29 microglial cell activation GO:0001774 9.76 TNF TLR3 IL4 IFNG
30 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.75 IFNG IFNB1 IFNA1
31 positive regulation of chemokine production GO:0032722 9.74 TNF TLR3 IL6
32 negative regulation of amyloid-beta clearance GO:1900222 9.71 TNF IFNG
33 negative regulation of lipid storage GO:0010888 9.71 TNF IL6
34 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.71 TNF IFNG
35 positive regulation of MHC class II biosynthetic process GO:0045348 9.71 IL4 IL10 IFNG
36 necroptotic signaling pathway GO:0097527 9.7 TNF TLR3
37 endothelial cell apoptotic process GO:0072577 9.7 TNF IL10
38 defense response GO:0006952 9.7 TNF TLR3 STAT2 STAT1 IFNB1 IFNA1
39 positive regulation of mononuclear cell migration GO:0071677 9.68 TNF IL4
40 type 2 immune response GO:0042092 9.68 IL4 IL10
41 negative regulation of cytokine production involved in immune response GO:0002719 9.67 TNF IL10
42 positive regulation of cellular respiration GO:1901857 9.67 IL4 IFNG
43 neuroinflammatory response GO:0150076 9.66 IL4 IFNG
44 regulation of immunoglobulin secretion GO:0051023 9.66 TNF CD40LG
45 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 TNF IL10
46 regulation of isotype switching GO:0045191 9.64 IL4 IL10
47 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.64 TNF IFNG
48 receptor biosynthetic process GO:0032800 9.63 TNF IL10
49 positive regulation of chemokine biosynthetic process GO:0045080 9.62 TNF TLR3 IL4 IFNG
50 positive regulation of vitamin D biosynthetic process GO:0060557 9.61 TNF IFNG

Molecular functions related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.56 IL6 IL4 IL10 F2
2 tumor necrosis factor receptor binding GO:0005164 9.33 TNF STAT1 CD40LG
3 cytokine activity GO:0005125 9.28 TNF IL6 IL4 IL10 IFNG IFNB1
4 cytokine receptor binding GO:0005126 9.13 IL4 IFNB1 IFNA1

Sources for Dengue Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....